nach oben

06.05.2024

Cognitive impairment and neurocognitive profiles among people living with HIV and HIV-negative individuals older over 50 years: a comparison of IHDS, MMSE and MoCA

verfasst von: Panpan Chen, Xin Xin, Shaotan Xiao, Hantao Liu, Xin Liu, Na He, Yingying Ding

Einloggen, um Zugang zu erhalten

Abstract

We aimed to examine the l differences in the assessment of neurocognitive impairment (NCI) using cognitive screening tools between PLWH and HIV-negative individuals and further compare the neurocognitive profiles between the two groups. This was baseline evaluation of Pudong HIV Aging Cohort, including 465 people living with HIV (PLWH) and 465 HIV-negative individuals aged over 50 years matched by age (± 3 years), sex and education. NCI was assessed using the Chinese version of Mini-mental State Examination (MMSE), the International HIV Dementia Scale (IHDS) and Beijing version of Montreal Cognitive Assessment (MoCA). In total, 258 (55.5%), 91 (19.6%), 273 (58.7%) of PLWH were classified as having NCI by the IHDS, MMSE and MoCA, compared to 90 (19.4%), 25 (5.4%), 135 (29.0%) of HIV-negative individuals, respectively (p < 0.05); such associations remained significant in multivariable analysis. PLWH showed a larger overlap of NCI detected by IHDS, MMSE, and MoCA. IHDS and MoCA detected almost all of the NCI detected by MMSE. IHDS-motor and psychomotor speeds and MoCA-executive function showed the greatest disparities between two groups. In multivariable analysis, older age and more depressive symptoms were positively associated with NCI regardless of the screening tools or HIV serostatus. PLWH over 50 years old display a higher prevalence of NCI and distinct neurocognitive profiles compared to HIV-negative individuals, despite viral suppression. Given the more considerable overlap in NCI classification in PLWH, it is advisable to choose one screening tool such as IHDS or MoCA to identify those potentially having NCI and then refer to more comprehensive neuropsychological assessment.

Nur mit Berechtigung zugänglich

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8bCrossRefPubMed

Aung HL, Siefried KJ, Gates TM, Brew BJ, Mao L, Carr A, Cysique LA (2022) Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not. EClinicalMedicine 56:101792. https://doi.org/10.1016/j.eclinm.2022.101792

Aung HL, Alagaratnam J, Chan P, Chow FC, Joska J, Falutz J, Letendre SL, Lin W, Muñoz-Moreno JA, Cinque P, Taylor J, Brew B, Winston A (2023) Cognitive health in persons with human immunodeficiency virus: the impact of early treatment, comorbidities, and aging. J Infect Dis 227(Supplement1):S38–S47. https://doi.org/10.1093/infdis/jiac388CrossRefPubMedPubMedCentral

Borrajo A, Svicher V, Salpini R, Pellegrino M, Aquaro S (2021) Crucial role of Central nervous system as a viral anatomical compartment for HIV-1 infection. Microorganisms 9(12):2537. https://doi.org/10.3390/microorganisms9122537CrossRefPubMedPubMedCentral

Burlacu R, Umlauf A, Luca A, Gianella S, Radoi R, Ruta SM, Marcotte TD, Ene L, Achim CL (2018) Sex-based differences in neurocognitive functioning in HIV-infected young adults. AIDS 32(2):217–225. https://doi.org/10.1097/QAD.0000000000001687CrossRefPubMed

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213. https://doi.org/10.1016/0165-1781(89)90047-4CrossRefPubMed

Chen PP, Wei XY, Tao L, Xin X, Xiao ST, He N (2023) Cerebral abnormalities in HIV-infected individuals with neurocognitive impairment revealed by fMRI. Sci Rep 13(1):10331. https://doi.org/10.1038/s41598-023-37493-3

Chiao S, Rosen HJ, Nicolas K, Wendelken LA, Alcantar O, Rankin KP, Miller B, Valcour V (2013) Deficits in self-awareness impact the diagnosis of asymptomatic neurocognitive impairment in HIV. AIDS Res Hum Retroviruses 29(6):949–956. https://doi.org/10.1089/AID.2012.0229CrossRefPubMedPubMedCentral

Ciccarelli N (2020) Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update? Infection. 48(1):37–42. https://doi.org/10.1007/s15010-019-01373-8

Dang C, Wei B, Long J, Zhou M, Han X, Zhao T (2015) Validity of the International HIV Dementia Scale as assessed in a socioeconomically underdeveloped region of Southern China: assessing the influence of educational attainment. Int J Infect Dis 33:56–61. https://doi.org/10.1016/j.ijid.2014.12.042CrossRefPubMed

de Souza EM, Buoniconti CS, Valim FC, Moura AS (2016) Risk factors for neurocognitive impairment in HIV-infected patients and comparison of different screening tools. Dement Neuropsychol 10(1):42–46. https://doi.org/10.1590/S1980-57642016DN10100008CrossRefPubMedPubMedCentral

Ding Y, Lin H, Shen W, Wu Q, Gao M, He N (2017) Interaction effects between HIV and aging on selective neurocognitive impairment. J Neuroimmune Pharmacol 12:661–669. https://doi.org/10.1007/s11481-017-9748-3CrossRefPubMed

Frain JA, Chen L (2018) Examining the effectiveness of a cognitive intervention to improve cognitive function in a population of older adults living with HIV: a pilot study. Ther Adv Infect Dis 5(1):19–28. https://doi.org/10.1177/2049936117736456CrossRefPubMed

Giacometti LL, Barker JM (2019) Comorbid HIV infection and alcohol use disorders: converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction. Brain Res 1723:146390. https://doi.org/10.1016/j.brainres.2019.146390CrossRefPubMedPubMedCentral

Green JE, Saveanu RV, Bornstein RA, Bornstein (2004) The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry 161(2):249–254. https://doi.org/10.1176/appi.ajp.161.2.249CrossRefPubMed

Joska JA, Witten J, Thomas KG, Robertson C, Casson-Crook M, Roosa H, Creighton J, Lyons J, McArthur J, Sacktor NC (2016) A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the USA and South Africa. AIDS Behav 20(8):1621–1631. https://doi.org/10.1007/s10461-016-1316-yCrossRefPubMedPubMedCentral

Joska JA, Dreyer AJ, Nightingale S, Combrinck MI, De Jager CA (2019) Prevalence of HIV-1 infection in an elderly rural population and associations with neurocognitive impairment. AIDS 33(11):1765–1771. https://doi.org/10.1097/QAD.0000000000002257CrossRefPubMed

Kellett-Wright J, Flatt A, Eaton P, Urasa S, Howlett W, Dekker M, Kisoli A, Duijinmaijer A, Thornton J, McCartney J, Yarwood V, Irwin C, Mukaetova-Ladinska E, Akinyemi R, Lwezuala B, Gray WK, Walker RW, Dotchin CL, Makupa P, Paddick SM (2021) Screening for HIV-associated neurocognitive disorder (HAND) in adults aged 50 and over attending a government HIV clinic in Kilimanjaro, Tanzania. Comparison of the International HIV Dementia Scale (IHDS) and IDEA six item dementia screen. AIDS Behav 25(2):542–553. https://doi.org/10.1007/s10461-020-02998-9CrossRefPubMed

Lam JO, Hou CE, Hojilla JC, Anderson AN, Gilsanz P, Alexeeff SE, Levine-Hall T, Hood N, Lee C, Satre DD, Silverberg MJ (2021) Comparison of dementia risk after age 50 between individuals with and without HIV infection. AIDS 35(5):821–828. https://doi.org/10.1097/QAD.0000000000002806CrossRefPubMed

Lopardo GD, Bissio E, Iannella Mdel C, Crespo AD, Garone DB, Cassetti LI (2009) Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. J Acquir Immune Defic Syndr 52(4):488–492. https://doi.org/10.1097/QAI.0b013e3181b06348CrossRefPubMed

Lyon ME, McCarter R, D’Angelo LJ (2009) Detecting HIV associated neurocognitive disorders in adolescents: what is the best screening tool? J Adolesc Health 44(2):133–135. https://doi.org/10.1016/j.jadohealth.2008.06.023CrossRefPubMed

Makinson A, Dubois J, Eymard-Duvernay S, Leclercq P, Zaegel-Faucher O, Bernard L, Vassallo M, Barbuat C, Gény C, Thouvenot E, Costagliola D, Ozguler A, Zins M, Simony M, Reynes J, Berr C (2020) Increased prevalence of neurocognitive impairment in aging people living with human immunodeficiency virus: the ANRS EP58 HAND 55–70 study. Clin Infect Dis 70(12):2641–2264CrossRefPubMed

McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67(6):699–714. https://doi.org/10.1002/ana.22053CrossRefPubMed

Molinaro M, Sacktor N, Nakigozi G, Anok A, Batte J, Kisakye A, Myanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Saylor D (2020) Utility of the International HIV Dementia Scale for HIV-associated neurocognitive disorder. J Acquir Immune Defic Syndr 83(3):278–283. https://doi.org/10.1097/QAI.0000000000002257CrossRefPubMedPubMedCentral

Montanucci C, Chipi E, Salvadori N, Rinaldi R, Eusebi P, Parnetti L (2021) HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version. J Neurol 268(12):4789–4795. https://doi.org/10.1007/s00415-021-10592-9CrossRefPubMedPubMedCentral

Mudra Rakshasa-Loots A, Whalley HC, Vera JH, Cox SR (2022) Neuroinflammation in HIV-associated depression: evidence and future perspectives. Mol Psychiatry 27(9):3619–3632. https://doi.org/10.1038/s41380-022-01619-2CrossRefPubMedPubMedCentral

Omeragic A, Kayode O, Hoque MT, Bendayan R (2020) Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders. Fluids Barriers CNS 17:1–30. https://doi.org/10.1186/s12987-020-00204-5

Paul R (2019) Neurocognitive phenotyping of HIV in the era of antiretroviral therapy. Curr HIV/AIDS Rep 16(3):230–235. https://doi.org/10.1007/s11904-019-00426-9CrossRefPubMedPubMedCentral

Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa MLG, Ximenes RCC, Sougey EB (2019) Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) in the elderly? Int Psychogeriatr 31(04):491–504. https://doi.org/10.1017/S1041610218001370CrossRefPubMed

Qiao X, Lin H, Chen X, Ning C, Wang K, Shen W, Xu X, Xu X, Liu X, He N, Ding Y (2019) Sex differences in neurocognitive screening among adults living with HIV in China. J Neurovirol 25(3):363–371. https://doi.org/10.1007/s13365-019-00727-0CrossRefPubMed

Rianawati S, Andriani N, Munir B, Raisa N (2021) Serial case of HIV associated neurocognitive disorder. J Neurol Sci 429:117683.CrossRef

Rubin LH, Maki PM (2019) HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy. Curr HIV/AIDS Rep 16(1):82–95. https://doi.org/10.1007/s11904-019-00421-0

Rubin LH, Gustafson D, Hawkins KL, Zhang L, Jacobson LP, Becker JT, Munro CA, Lake JE, Martin E, Levine A, Brown TT, Sacktor N, Erlandson KM (2019) Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study. Neurology 93(3):e261–e271. https://doi.org/10.1212/WNL.0000000000007779CrossRefPubMedPubMedCentral

Sacktor N (2018) Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neurovirol 24(2):141–145. https://doi.org/10.1007/s13365-017-0556-6CrossRefPubMed

Sacktor N, Robertson K (2014) Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Curr Opin HIV AIDS 9(6):517–520. https://doi.org/10.1097/COH.0000000000000102CrossRefPubMedPubMedCentral

Saloner R, Campbell LM, Serrano V, Montoya JL, Pasipanodya E, Paolillo EW, Franklin D, Ellis RJ, Letendre SL, Collier AC, Clifford DB, Gelman BB, Marra CM, McCutchan JA, Morgello S, Sacktor N, Jeste DV, Grant I, Heaton RK, Moore DJ (2019) Neurocognitive SuperAging in older adults living with HIV: demographic, neuromedical and everyday functioning correlates. J Int Neuropsychol Soc 25(05):5. https://doi.org/10.1017/S1355617719000018CrossRef

Santos G, Locatelli I, Métral M, Berney A, Nadin I, Calmy A, Tarr P, Gutbrod K, Hauser C, Brugger P, Kovari H, Kunze U, Stoeckle M, Früh S, Schmid P, Rossi S, Di Benedetto C, Du Pasquier R, Darling K, Cavassini M (2021) The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. Int J STD AIDS 32(8):729–739. https://doi.org/10.1177/0956462420987434CrossRefPubMed

Selvaraj N, Chidambaram Y, Dhas CPCJ, Nekkanti A, Velammal P, Kumar B, Alagesan M (2023) Prevalence of asymptomatic HIV associated neurocognitive disorder in a tertiary care hospital in South India: a single centre observational study. Mediterr J Infect Microb Antimicrob 12(11). https://doi.org/10.4274/mjima.galenos

Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C (2018) Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med 10(4):246–252. https://doi.org/10.1111/j.1468-1293.2008.00679.xCrossRef

Sundermann EE, Heaton RK, Pasipanodya E, Moore RC, Paolillo EW, Rubin LH, Ellis R, Moore DJ (2018) Sex differences in HIV-associated cognitive impairment. AIDS 32(18):2719–2726. https://doi.org/10.1097/QAD.0000000000002012

Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A (2018) Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. HIV Med 9(7):455–464. https://doi.org/10.1111/hiv.12622CrossRef

Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ (2015) Relationship between the Montreal Cognitive Assessment and Mini-mental State examination for assessment of mild cognitive impairment in older adults. BMC Geriatr 15(1). https://doi.org/10.1186/s12877-015-0103-3

Underwood J, De Francesco D, Cole JH, Caan MWA, van Zoest RA, Schmand BA, Sharp DJ, Sabin CA, Reiss P, Winston A (2019) Validation of a novel multivariate method of defining HIV-associated cognitive impairment. Open Forum Infect Dis 6(6). https://doi.org/10.1093/ofid/ofz198

Williams ME, Joska JA, Amod AR, Paul RH, Stein DJ, Ipser JC, Naudé PJW (2020) The association of peripheral immune markers with brain cortical thickness and surface area in South African people living with HIV. J Neurovirol 26(6):908–919. https://doi.org/10.1007/s13365-020-00873-wCrossRefPubMed

Wu Z, Wang Y, Detels R, Bulterys M, McGoogan JM (eds) (2020) National HIV/AIDS case management: HIV/AIDS in China—epidemiology, prevention and treatment. Singapore: Springer 491–502. https://doi.org/10.1007/978-981-13-8518-6

Titel: Cognitive impairment and neurocognitive profiles among people living with HIV and HIV-negative individuals older over 50 years: a comparison of IHDS, MMSE and MoCA
verfasst von: Panpan Chen
Xin Xin
Shaotan Xiao
Hantao Liu
Xin Liu
Na He
Yingying Ding
Publikationsdatum: 06.05.2024
Verlag: Springer International Publishing
Erschienen in: Journal of NeuroVirology
Print ISSN: 1355-0284
Elektronische ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-024-01205-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen